Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration

Neurobiology of Disease

Volumn 37, Issue 2, 2010, Pages 307-313

  Zhu, Wen ^a   Li, Xuping ^a   Xie, Wenjie ^a   Luo, Feifei ^a   Kaur, Deepinder ^b   Andersen, Julie K ^b   Jankovic, Joseph ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Buck Institute for Research in Aging   (United States)

Author keywords

DMT1; Ferritin; Iron chelation; Parkinson's disease; UPS impairment

Indexed keywords

FERRITIN; FERRITIN HEAVY CHAIN; FERROUS ION; IRON; LACTACYSTIN; MALONALDEHYDE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; IMMUNOCYTOCHEMISTRY; IRON CHELATION; MOUSE; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; STEREOLOGY; WESTERN BLOTTING;

ACETYLCYSTEINE; ANIMALS; APOFERRITINS; CATION TRANSPORT PROTEINS; CHELATION THERAPY; CORPUS STRIATUM; CYSTEINE PROTEINASE INHIBITORS; CYTOPROTECTION; DOPAMINE; GENE EXPRESSION REGULATION; GENE THERAPY; IRON METABOLISM DISORDERS; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA;

EID: 73049109985     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.09.024     Document Type: Article

References (45)

1. Andersen J.K. Iron dysregulation and Parkinson's disease. J. Alzheimers Dis. S6 (2004) S47-S52
2. Avramovich-Tirosh Y., Amit T., Bar-Am O., Zheng H., Fridkin M., and Youdim M.B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 100 (2007) 490-502
3. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., Gray T., Topham I., Fone K., Rezvani N., Mee M., Soane T., Layfield R., Sheppard P.W., Ebendal T., Usoskin D., Lowe J., and Mayer R.. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28 (2008) 8189-8198
4. Berg D., and Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 21 (2006) 1299-1310
5. Benarroch E.E. Brain iron homeostasis and neurodegenerative disease. Neurology 72 (2009) 1436-1440
6. Bove J., Zhou C., Jackson-Levis V., Tayor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., and Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60 (2006) 260-264
7. Chen Y.F., Zhu G.Q., Wang M., Cheng H., Zhou A., Wang N., Fang N., Wang X.C., Xiao X.Q., Chen Z.W., and Li Q.L. Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP (+)-elicited apoptosis. Neurosci. Res. 63 (2004) 52-58
8. Chinnery P.F., Crompton D.E., Birchall D., Jackson M.J., Coulthard A., Lombès A., Quinn N., Wills A., Fletcher N., Mottershead J.P., Cooper P., Kellett M., Bates D., and Burn J. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130 (2007) 110-119
9. Connor J.R., Boeshore K.L., Benkovic S.A., and Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J. Neurosci. Res. 37 (1994) 461-465
10. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., and Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28 (2001) 350-354
11. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
12. Du Y., Li X., Yang D., Zhang X., Chen S., Huang K., and Le W. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp. Biol. Med. (Maywood) 233 (2008) 881-890
13. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Agid Y., and Hirsch E.C. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83 (2002) 320-330
14. Ferris C.D., Jaffrey S.R., Sawa A., Takahashi M., Brady S.D., Barrow R.K., Tysoe S.A., Wolosker H., Barañano D.E., Doré S., Poss K.D., and Snyder S.H. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat. Cell Biol. 1 (1999) 152-157
15. Gal S., Zheng H., Fridkin M., and Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95 (2005) 79-88
16. Gotz M.E., Double K., Gerlach M., Youdim M.B., and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012 (2004) 193-208
17. Gupta A., Dawson V.L., and Dawson T.M. What causes cell death in Parkinson's disease?. Ann. Neurol. 64 (2008) S3-15
18. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo, a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
19. Levy O.A., Malagelada C., and Greene L.A. Cell death pathways in Parkinson's disease, proximal triggers, distal effectors, and final steps. Apoptosis 14 (2009) 478-500
20. Li X., Du Y., Fan X., Yang D., Luo G., and Le W. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J. Neuropathol. Exp. Neurol. 67 (2008) 933-944
21. Lin P.H., Chiang M.T., and Chau L.Y. Ubiquitin-proteasome system mediates heme oxygenase-1 degradation through endoplasmic reticulum-associated degradation pathway. Biochim. Biophys. Acta 1783 (2008) 1826-1834
22. Mandel S., Maor G., and Youdim M.B. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice, effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin 3-gallate. J. Mol. Neurosci. 24 (2004) 401-416
23. Martin W.R., Wieler M., and Gee M. Midbrain iron content in early Parkinson disease, a potential biomarker of disease status. Neurology 70 (2008) 1411-1417
24. Maruyama W., Shamoto-Nagai M., Akao Y., Riederer P., and Naoi M. The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells. J. Neural Transm. S70 (2006) 125-132
25. McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., and Di Monte D.A. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J. Neurochem. 93 (2005) 1030-1037
26. McNaught K.S., and Olanow C.W. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging 27 (2006) 530-545
27. Nunez M.T., Nunez-Millacura C., Tapia V., Munoz P., Mazariegos D., Arredondo M., Munoz P., Mura C., and Maccioni R.B. Iron-activated iron uptake, a positive feedback loop mediated by iron regulatory protein 1. Biometals 16 (2003) 83-90
28. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., and Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68 (2007) 1820-1825
29. Ortega R., Cloetens P., Devès G., Carmona A., and Bohic S. Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS ONE 2 (2007) e925
30. Paxinos G., and Franklin K.B. The Mouse Brain in Stereotaxic Coordinates. Second ed. (2001), San Diego Academic
31. Peng J., Peng L., Stevenson F.F., Doctrow S.R., and Andersen J.K. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J. Neurosci. 27 (2007) 6914-6922
32. Rhodes S.L., and Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis. 32 (2008) 183-195
33. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nuñez M.T., Garrick M.D., Raisman-Vozari R., and Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 18578-18583
34. Schneider S.A., Bhatia K.P., and Hardy J. Complicated recessive dystonia parkinsonism syndromes. Mov. Disord. 24 (2009) 490-499
35. Tarohda T., Ishida Y., Kawai K., Yamamoto M., and Amano R. Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats. Anal. Bioanal. Chem. 383 (2005) 224-234
36. Thomas M., and Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr. Opin. Neurol. 17 (2004) 437-442
37. Thomas M., Hayflick S.J., and Jankovic J. Clinical heterogeneity of neurodegeneration with iron accumulation-1 (Hallervorden-Spatz Syndrome) and pantothenate kinase associated neurodegeneration (PKAN). Mov. Disord. 19 (2004) 36-42
38. Thompson K., Menzies S., Muckenthaler M., Torti F.M., Wood T., Torti S.V., Hentze M.W., Beard J., and Connor J. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71 (2003) 46-63
39. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C., and Baekelandt V. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol. Ther. 14 (2006) 716-723
40. Wang J., Fillebeen C., Chen G., Biederbick A., Lill R., and Pantopoulos K. Iron-dependent degradation of apo-IRP1 by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 27 (2007) 2423-2430
41. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 14 (1993) 275-285
42. Zecca L., Gallorini M., Schünemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., and Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76 (2001) 1766-1773
43. Zhang X., Xie W., Qu S., Pan T., Wang X., and Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333 (2005) 544-549
44. Zhang S., Wang J., Song N., Xie J., and Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol. Aging 30 (2009) 1466-1476
45. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., and Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21 (2007) 3835-3844